You are here

Article Text

Article menu
Download PDFPDF
Hepatology
Transient elastography predicts fibrosis progression in patients with recurrent hepatitis C after liver transplantation
  1. C Rigamonti1,
  2. M F Donato1,
  3. M Fraquelli2,
  4. F Agnelli1,
  5. G Ronchi1,
  6. G Casazza3,
  7. G Rossi4,
  8. M Colombo1
  1. 1
    First Division of Gastroenterology, AM & A Migliavacca Center for Liver Disease, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena and University of Milan, Italy
  2. 2
    Second Division of Gastroenterology, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena and University of Milan, Italy
  3. 3
    Istituto di Statistica Medica e Biometria, University of Milan, Milan, Italy
  4. 4
    Liver Transplant Unit, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena and University of Milan, Italy
  1. Dr Cristina Rigamonti, First Division of Gastroenterology, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Via Sforza, 35 – 20122 Milano, Italy; crigamo{at}tin.it

Abstract

Objective: Transient elastography (TE) allows non-invasive evaluation of the severity of liver disease in patients with chronic hepatitis C. This procedure, however, warrants further validation in the setting of liver transplantation (LT), including patients under follow-up for recurrent hepatitis C.

Setting: Tertiary referral hospital.

Patients: 95 patients (75 males) transplanted for end-stage liver disease due to hepatitis C virus.

Interventions: Paired liver biopsy (LB) and TE were carried out 6–156 (median, 35) months after LT. 40 patients with recurrent hepatitis C sequentially evaluated 6–21 months apart.

Main outcome measures: Clinical, laboratory and graft histological features influencing TE results.

Results: Median TE values were 7.6 kPa in the 90 patients with a successful TE examination, being 5.6 kPa in the 30 patients with Ishak fibrosis score (S) of 0–1, 7.6 kPa in the 38 with S2–3; 16.7 kPa in the 22 with S4–6, (p<0.0001). Areas under the ROC curves were 0.85 (95% CI, 0.76 to 0.92) for S⩾3, 0.90 (95% CI, 0.82 to 0.95) for S⩾4 with 7.9 and 11.9 kPa optimal TE cut-off (81% and 82% sensitivity, 88% and 94% negative predictive value, respectively). Fibrosis, necroinflammatory activity and higher than 200 IU/l gamma-glutamyl transpeptidase levels independently influenced TE results. During post-LT follow-up, TE results changed in parallel with grading (r = 0.63) and staging (r = 0.71), showing 86% sensitivity and 92% specificity in predicting staging increases.

Conclusions: TE accurately predicts fibrosis progression in LT patients with recurrent hepatitis C, suggesting that protocol LB might be avoided in patients with improved or stable TE values during follow-up.

https://doi.org/10.1136/gut.2007.135046

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Funding: This study was funded, in part, by an unrestricted grant from Roche S.P.A., Italy and a generous contribution by Mr Aldo Antognozzi and Consorzio Trapianti d’Organo.

    • Competing interests: None.

    • Ethics approval: Approval for this study was given by the Ethics Committee of Fondazione IRCCS Ospedale Maggiore Policlinco, Mangialli e Regina Elena.

    Linked Articles

    • Digest
      Digest
      Robin Spiller Magnus Simren
      Gut 2008; 57 1-2 Published Online First: 13 May 2008.